Proteome Sciences (PRM) AI Stock Analysis

• Market Cap: £9.45M
• Dividend Yield: N/A
• Average Volume (3M): 476.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: 12.19%
• EPS Growth: 18.12%
• Country: UK
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 295,182,040
• 10 Day Avg. Volume: 209,671
• 30 Day Avg. Volume: 476,642
• PEG Ratio: -0.08
• Price to Book (P/B): -1.54
• Price to Sales (P/S): 2.05
• P/FCF Ratio: -9.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: 3.50p ▲(22.81% Upside)

The score is primarily held down by very weak financial fundamentals (negative profitability, negative equity, and negative operating/free cash flow). Technicals are supportive with price above key moving averages and positive MACD, but the elevated RSI signals overbought risk. Valuation is constrained by a negative P/E and no dividend yield data.

Positive Factors

Specialized proteomics niche

Deep technical focus on mass spectrometry proteomics and biomarker discovery represents a durable competitive advantage. This expertise is hard to replicate, supports long-term client relationships with pharma/biotech, and positions the firm in growing personalized medicine workflows.

Fee-for-service contract model

A fee-for-service contract research model creates repeatable, project-based revenue streams and multi-client exposure across pharma, biotech, and academia. Durable client engagements and potential licensing of proprietary tools support steadier top-line predictability over months to years.

Reported revenue and EPS growth

Reported positive revenue and EPS growth metrics suggest improving operational traction and demand for services. If sustained, these trends can help rebuild margins and reduce reliance on external funding, supporting medium-term financial recovery and operational scaling.

Negative Factors

Negative shareholders' equity

Negative equity is a serious solvency flag that constrains strategic options. It raises refinancing and covenant risk, limits ability to invest in R&D or capacity, and can force dilutive or costly financing solutions that impair long-term shareholder value.

Weak operating and free cash flow

Persistent negative operating and free cash flow indicate the business does not self-fund operations or growth. This creates dependency on external capital, increases financing risk, and can constrain investment in sales, technology, or service capacity essential for sustained competitiveness.

Negative profitability and declining revenue

Declining revenue and negative EBIT/net margins show structural profit generation problems. Without margin recovery or revenue stabilization, the company may struggle to cover fixed costs and reinvest in capabilities, weakening long-term viability in a competitive diagnostics market.

Proteome Sciences Business Overview & Revenue Model

Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

How the Company Makes Money

Proteome Sciences generates revenue primarily through its contract research services, which involve offering proteomics analysis and biomarker discovery to pharmaceutical and biotechnology companies. These services are often provided on a fee-for-service basis, where clients pay for specific projects or studies tailored to their research needs. Additionally, the company may earn income from collaborations and partnerships with academic institutions and industry players, enabling shared research initiatives and technology licensing. Furthermore, Proteome Sciences could also monetize its proprietary technologies and software tools through licensing agreements, contributing to its overall revenue stream.

Proteome Sciences Financial Statement Overview

Summary

Proteome Sciences is facing substantial financial challenges across all financial statements. Declining revenues, negative profitability, and high debt levels indicate significant business risks. The negative equity and cash flow issues further exacerbate the company's financial instability.

Income Statement

The company has experienced declining revenue with a decrease from 5.03 million to 4.89 million over the last year, indicating a negative revenue growth rate. The negative EBIT and net income margins highlight ongoing operational challenges with profitability. These factors indicate financial instability in the income statement.

Balance Sheet

The company has a negative stockholders' equity, indicating that liabilities exceed assets, which is a significant concern. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt level suggests potential solvency issues. This balance sheet position suggests high financial risk.

Cash Flow

Operating cash flow is negative, and free cash flow has worsened, indicating cash flow difficulties. The free cash flow to net income ratio is negative, reflecting challenges in generating cash relative to net income. These factors demonstrate weak cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.53M	4.89M	5.03M	23.74B	22.59B	16.95B
Gross Profit	-32.00K	670.00K	1.65M	4.77M	2.96M	2.58M
EBITDA	-1.45M	-1.51M	-1.14M	2.13M	625.00K	714.00K
Net Income	-3.33M	-3.41M	-2.44M	1.32M	72.00K	295.00K
Balance Sheet
Total Assets	8.35M	9.21M	11.46M	12.43M	10.04M	9.09M
Cash, Cash Equivalents and Short-Term Investments	263.00K	1.13M	2.03M	3.99M	2.39M	2.21M
Total Debt	15.39M	14.52M	13.47M	11.91M	11.69M	11.04M
Total Liabilities	16.93M	15.72M	14.52M	13.28M	12.82M	12.45M
Stockholders Equity	-8.58M	-6.52M	-3.07M	-843.00K	-2.77M	-3.36M
Cash Flow
Free Cash Flow	-1.48M	-1.05M	-718.00K	2.14B	8.80B	-9.07B
Operating Cash Flow	-1.21M	-826.00K	-481.00K	3.88B	10.52B	-7.74B
Investing Cash Flow	-273.00K	-224.00K	-424.00K	-21.67B	4.27B	-18.38B
Financing Cash Flow	368.00K	151.00K	-1.06M	-209.00K	-400.00K	-146.00K

Proteome Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Positive. The current price of 2.85 is above the 20-day moving average (MA) of 2.58, above the 50-day MA of 2.12, and above the 200-day MA of 2.79, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 65.00 is Neutral, neither overbought nor oversold. The STOCH value of 60.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PRM.

Proteome Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRCI	58 Neutral	£11.35M	-0.31	-122.54%	―	-57.03%	-15.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLBX	48 Neutral	£11.93M	-0.21	-87.18%	―	29.64%	28.51%
PRM	46 Neutral	£9.45M	-2.83	―	―	12.19%	18.12%
GDR	44 Neutral	£9.01M	-0.94	-153.92%	―	90.42%	79.21%
OPTI	43 Neutral	£6.09M	-42.14	-2.42%	―	―	―
GENI	41 Neutral	£5.59M	-0.84	-181.41%	―	12.12%	54.24%

Proteome Sciences Corporate Events

Proteome Sciences Wins Two More Major GCLP Contracts Worth Over $1.5m

Proteome Sciences has secured two additional substantial GCLP contracts worth over $1.5 million, following an earlier announcement in December 2025, with trial samples scheduled to be shipped in late Q1 and most of the work to be completed during 2026. Management highlighted sustained strong demand from major biopharma clients in both the US and Europe, indicating that these new wins, combined with previously announced contracts, provide a robust order book that underpins the company’s revenue visibility and operational outlook through 2026.

The most recent analyst rating on (GB:PRM) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.

Proteome Sciences Secures Major Biopharma Contract

Proteome Sciences has secured a significant contract with a US biopharmaceutical company to develop a new assay using its mass spectrometry services in Frankfurt, Germany. This contract, which adheres to Good Clinical Laboratory Practice standards, is expected to enhance the company’s positioning in the industry by increasing demand for its services, with potential for further contracts in the coming years.

The most recent analyst rating on (GB:PRM) stock is a Hold with a £2.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.

Proteome Sciences Appoints New Nominated Adviser and Broker

Proteome Sciences has announced the appointment of SP Angel Corporate Finance LLP as its new Nominated Adviser and sole Broker, effective immediately. This strategic move is expected to enhance the company’s development efforts and strengthen its market position, potentially benefiting stakeholders by providing improved financial guidance and support.

The most recent analyst rating on (GB:PRM) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Proteome Sciences stock, see the GB:PRM Stock Forecast page.